Evidence map›Paper›PMID 24239684›Full record

ReviewCryobiology2014

Mechanisms of cryoablation: clinical consequences on malignant tumors.

J G Baust, A A Gage, T E Bjerklund Johansen, J M Baust

Abstract readLetterReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cryobiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 220 citations in OpenAlex.

  1. Cryotherapy for liver metastases.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Current Status of Cryoablation in Prostate Cancer Management.Clinical Medicine Insights. Oncology · 2025
    Review
  18. Review
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

J G BaustInstitute of Biomedical Technology, State University of New York at Binghamton, Binghamton, NY 13902, United States; Department of Biological Sciences, Binghamton University, Binghamton, NY 13902, United States. Electronic address: baustcryo@aol.com.
A A GageDepartment of Surgery, State University of New York at Buffalo, Medical School, Buffalo, NY 14214, United States.
T E Bjerklund JohansenUrology Department, Cancer and Surgery Clinic, Oslo University Hospital, Oslo, Norway.
J M BaustCPSI Biotech, Owego, NY 13827, United States.
Cell Preservation Services (United States) · USOslo University Hospital · NOUniversity at Buffalo, State University of New York · US

Funding

A Resorbable Cryoprobe Provides a Salvage Therapeutic OptionR43CA123993 · NCI · CELL PRESERVATION SERVICES, INC. · PI SNYDER, KRISTI K · 2007 to 2007
$169k
NCI NIH HHS R43 CA123993
6 · The paper itself

Abstract

While the destructive actions of a cryoablative freeze cycle are long recognized, more recent evidence has revealed a complex set of molecular responses that provides a path for optimization. The importance of optimization relates to the observation that the cryosurgical treatment of tumors yields success only equivalent to alternative therapies. This is also true of all existing therapies of cancer, which while applied with curative intent; provide only disease suppression for periods ranging from months to years. Recent research has led to an important new understanding of the nature of cancer, which has implications for primary therapies, including cryosurgical treatment. We now recognize that a cancer is a highly organized tissue dependent on other supporting cells for its establishment, growth and invasion. Further, cancer stem cells are now recognized as an origin of disease and prove resistant to many treatment modalities. Growth is dependent on endothelial cells essential to blood vessel formation, fibroblasts production of growth factors, and protective functions of cells of the immune system. This review discusses the biology of cancer, which has profound implications for the diverse therapies of the disease, including cryosurgery. We also describe the cryosurgical treatment of diverse cancers, citing results, types of adjunctive therapy intended to improve clinical outcomes, and comment briefly on other energy-based ablative therapies. With an expanded view of tumor complexity we identify those elements key to effective cryoablation and strategies designed to optimize cancer cell mortality with a consideration of the now recognized hallmarks of cancer.

Indexed as

ApoptosisCombined Modality TherapyCryosurgeryHumansMaleNeoplastic Stem CellsNeovascularization, PathologicProstateProstatic NeoplasmsTumor MicroenvironmentCryoablationCryosensitizersCryosurgeryCryotherapyProstate cancer

Identifiers

PMID24239684
PMCPMC3976170
OpenAlexW1985256611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.